NasdaqCM - Nasdaq Real Time Price USD

Mainz Biomed N.V. (MYNZ)

3.2000

+0.0500

+(1.59%)

At close: 4:00:00 PM EDT

3.1300

-0.07

(-2.19%)

After hours: 6:19:58 PM EDT

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partnerships with industry leaders mark key progress Company highlights its early accomplishments for 2025 BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics di

GlobeNewswire 23 days ago

MYNZ
+1.59%
Mainz enrols first subject in study to evaluate colorectal cancer test

The trial is set to conclude subject enrolment by the second half of this year.

Medical Device Network 27 days ago

MYNZ
+1.59%
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the first patient has been enrolled in

GlobeNewswire 28 days ago

MYNZ
+1.59%
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular

GlobeNewswire last month

MYNZ
+1.59%
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to support Colorectal Cancer Awareness Month in March. Detecting colorectal cancer (CRC) in its early stages significantly improves survival rates, making awareness and proactive screening essential in the fight against this disease. Globally, CRC is the second lea

GlobeNewswire last month

MYNZ
+1.59%
Mainz Biomed Expands into Switzerland with labor team w

Partnership to Launch DNA-Based Colorectal Cancer Screening TestBERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with labor team w ag (“labor team”), a renowned diagnostic laboratory based in Goldach, Switzerland. This collaboration introduces ColoAlert®, a DNA-based colorectal cance

GlobeNewswire 2 months ago

MYNZ
+1.59%
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in GermanyBERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to share that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer (CRC) screening test. Starting this January, patients acr

GlobeNewswire 2 months ago

MYNZ
+1.59%
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in

GlobeNewswire 2 months ago

MYNZ
+1.59%
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the la

GlobeNewswire 3 months ago

MYNZ
+1.59%
Mainz Biomed partners with Quest for colorectal cancer screening test

The test leverages PCR technology to detect cancerous DNA in stool samples.

Medical Device Network 4 months ago

MYNZ
+1.59%
DGX
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz B

GlobeNewswire 4 months ago

MYNZ
+1.59%
DGX
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Class A warrant to purchase one ordinary share, and one Class B warrant to purchase one o

GlobeNewswire 4 months ago

MYNZ
+1.59%
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Series A warrant to purchase one ordinary share, and one series B warrant to purchase one ordinary share for gro

GlobeNewswire 4 months ago

MYNZ
+1.59%
Mainz Biomed Announces Stock Split

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The r

GlobeNewswire 4 months ago

MYNZ
+1.59%
The Oncology Bet Is Already Paying Off For Pfizer

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.

Benzinga 5 months ago

PFE

MRNA

MYNZ
+1.59%
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz B

GlobeNewswire 5 months ago

MYNZ
+1.59%
TMO
Mainz Biomed restructured operations, implemented cost reductions

In September 2024, Mainz Biomed (MYNZ) announced feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional average risk population. In October 2024, the Company made the strategic decision to focus its efforts on three key initiatives for the remainder of 2024 and into 2025 in order to maximize shareholder value. Those initiatives are: The continued growth of its ColoAlert business in Europe; Development of its

TipRanks 5 months ago

MYNZ
+1.59%
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular g

GlobeNewswire 5 months ago

MYNZ
+1.59%
Mainz Biomed Secures Additional $1.5M Funding

Mainz Biomed B.V. (MYNZ) has released an update. Mainz Biomed B.V. has entered into a supplemental agreement with YA II PN, LTD. for a fourth Pre-Paid Advance of $1.5 million, following three previous promissory notes totaling $14.3 million. The funds from this latest note are designated for working capital and general corporate purposes, ensuring the company’s continued operations without shareholder approval for issuance. The transaction is exempt from registration under the Securities Act, in

TipRanks 6 months ago

MYNZ
+1.59%
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-BadenBERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercializ

GlobeNewswire 6 months ago

MYNZ
+1.59%

Performance Overview

Return	MYNZ	S&P 500 (^GSPC)
YTD	-25.93%	-6.75%
1-Year	+255.95%	+8.15%
3-Year	-75.10%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mainz Biomed N.V. (MYNZ)

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Mainz enrols first subject in study to evaluate colorectal cancer test

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed partners with Quest for colorectal cancer screening test

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Stock Split

The Oncology Bet Is Already Paying Off For Pfizer

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed restructured operations, implemented cost reductions

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Secures Additional $1.5M Funding

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Performance Overview